Europe — EMA
Nuwiq (Simoctocog Alfa)
Simoctocog alfa, the active ingredient in Nuwiq, is a Factor VIII concentrate presented as a sterile solution for intravenous use. It is used to treat and prevent bleeding episodes in individuals with hemophilia A.
Request sourcing
What is Simoctocog Alfa?
Simoctocog alfa, the active ingredient in Nuwiq, is a Factor VIII concentrate presented as a sterile solution for intravenous use. It is used to treat and prevent bleeding episodes in individuals with hemophilia A. GNH USA supplies Nuwiq as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.
GNH USA supplies Nuwiq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.
What is Simoctocog Alfa used for?
Nuwiq is a recombinant Factor VIII product that addresses disorders of the coagulation cascade associated with hemophilia A. - Hemophilia A (severe): Provides replacement therapy to control and prevent severe bleeding episodes. - Hemophilia A (moderate) : - - blank \\ \
